3:49 PM
 | 
Jan 14, 2019
 |  BC Extra  |  Company News

AZ's Bohen departing after cancer-focused tenure

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Sean Bohen is leaving as CMO and EVP of global medicines development after a tenure marked by mixed results for the pharma's checkpoint inhibitor.

Shortly after Bohen joined the pharma in August 2015, AstraZeneca reduced its core SG&A expenses to boost investment in oncology (see "AZ Cutting Costs, Boosting Oncology Investment").

Successes during Bohen's tenure include the Phase III PACIFIC trial of Imfinzi durvalumab, which led the anti-PD-L1 mAb to become the only FDA-approved drug to treat stage III...

Read the full 407 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >